NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Tizona Therapeutics

Tizona Therapeutics

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://tizonatx.com

Last Round

Corporate Funding

Jul 21, 2020

Est. Valuation

$601.2M

Total Funding Raised

$475M

Company Overview

Tizona Therapeutics is a biotechnology company that develops first-in-class immunotherapies to treat cancer and autoimmune diseases by modulating immunosuppressive cell activity in the tumor microenvironment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immunotherapyoncologybiotechnologyantibody therapeuticsdrug discoveryclinical trialstumor microenvironmentbiopharmafirst-in-classdrug developmentclinical-stage biotechcancer researchmonoclonal antibodiesimmune suppressionbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tizona Therapeutics Comparables

Compare Tizona Therapeutics with similar companies based on industry and business-model similarity.

Tizona Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Trishula Therapeutics
92%
Immune-Onc Therapeutics
84%
OncoResponse
81%

Tizona Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingJul 21, 2020
StrategicJan 3, 2019
Series BMar 8, 2016
Series AJan 1, 2016

Key People

Founding team and executive leadership

Christine Muchi O'Brien

Chief Executive Officer

Executive Team

Tizona Therapeutics Investors

Notable investors and investment history

Tizona Therapeutics investors
InvestorRounds
MPM CapitalSeries B
InterWest PartnersSeries B, Series A
Lightstone VenturesSeries B
MPM BioImpactSeries B, Series A
Amgen VenturesSeries B, Series A
AbingworthSeries B
Canaan PartnersSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 3, 2019

    $105M round led by AbbVie and Astellas Venture Management.

  • Mar 8, 2016

    $43M round led by Canaan Partners and Abingworth.

Tizona Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Tizona Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Tizona Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range23
Year Founded2014
Last FundingJul 21, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.